SCHEMBL4423600

SCHEMBL4423600

[CH2]Cc1c(C)[nH]c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.65
CYP3A4 P08684 1/20 0.65
ALDH1A1 P00352 4/20 0.62
HTT P42858 3/20 0.62
TSHR P16473 1/20 0.62
KDM4E B2RXH2 3/20 0.61
POLB P06746 2/20 0.61
GAA P10253 2/20 0.59
HTR6 P50406 1/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
AHR P35869 1/20 0.55
KRAS P01116 1/20 0.53
KMT2A Q03164 3/20 0.48
HPGD P15428 2/20 0.48
PABPC1 P11940 1/20 0.48
ALOX15 P16050 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
SLC2A1 P11166 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9780083 0.85 HTT (0.69) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL18383120 0.83 MAPT (0.69) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL8722151 0.83 KDM4E (0.70) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL669111 0.82 HTT (0.73) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL26473490 0.80 MAPT (0.65) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL9664534 0.80 MAPT (0.65) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL3196770 0.80 ALDH1A1 (0.73) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL12641259 0.80 MAPT (0.65) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL6402986 0.79 MAPT (0.59) MAPTCYP3A4ALDH1A1HTTTSHR
SCHEMBL28138965 0.78 ALDH1A1 (0.71) MAPTCYP3A4ALDH1A1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1682538-A4 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S BIO PTE LTD (SG) 2009-05-27 EP claimed
US-20080070954-A1 Acylurea Connected And Sulfonylurea Connected Hydroxamates S*BIO PTE LTD. (SG) 2008-03-20 US claimed
EP-1685094-A4 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S BIO PTE LTD (SG) 2007-08-22 EP claimed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US claimed
EP-1685094-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*Bio Pte Ltd (SG) 2006-08-02 EP claimed
EP-1682538-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*Bio Pte Ltd (SG) 2006-07-26 EP claimed
WO-2005040101-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*BIO PTE LTD (SG) 2005-05-06 WO claimed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 WO claimed
CN-113660932-B Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same 景凯生物科技股份有限公司 2024-07-12 CN disclosed
CN-113660932-A Phenyl derivatives with pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same 景凯生物科技股份有限公司 2021-11-16 CN disclosed
CN-108341823-A A kind of spiro indole -3,3 '-pyrrolidines and its synthetic method 中国科学院兰州化学物理研究所苏州研究院 2018-07-31 CN disclosed
CN-102584673-B Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide NOVARTIS AG 2014-08-06 CN disclosed
CN-103497184-A Pyrrolo-and thiazolo-pyridine compounds as HIF modulators FIBROGEN INC 2014-01-08 CN disclosed
CN-101641328-A Polymorphs of N-hydroxy-3- [ 4- [ [ [ 2- (2-methyl-1H-indol-3-yl) ethyl ] amino ] methyl ] phenyl ] -2E-2-propenamide NOVARTIS AG CH 2010-02-03 CN disclosed
EP-1685094-A4 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S BIO PTE LTD (SG) 2007-08-22 EP disclosed
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications A*BIO PTE LTD. (SG) 2007-07-19 US disclosed
EP-1685094-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*Bio Pte Ltd (SG) 2006-08-02 EP disclosed
EP-1682538-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*Bio Pte Ltd (SG) 2006-07-26 EP disclosed
WO-2005040101-A1 ACYLUREA CONNECTED AND SULFONYLUREA CONNECTED HYDROXAMATES S*BIO PTE LTD (SG) 2005-05-06 WO disclosed
WO-2005040161-A1 BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS S*BIO PTE LTD (SG) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070954-A1 Acylurea Connected And Sulfonylurea Connected Hydroxamates HDAC1, HDAC3, HDAC4 MAPT 4594/4885CYP3A4 3904/4885ALDH1A1 1020/4885
US-20070167499-A1 Biaryl linked hydroxamates: preparation and pharmaceutical applications HDAC1, HDAC11, HDAC2 MAPT 3965/4885CYP3A4 1201/4885ALDH1A1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.